 [6] 
  By a statement of claim dated July 6, 2001, Apotex commenced an action against the Defendants for damages and/or profits on the basis that Apotex's generic version of naproxen was held off the market by reason of the Defendants' prohibition application. Apotex's claim is made pursuant to s. 8 of the Patented Medicines (Notice of Compliance) Regulations, SOR/98-166 (NOC Regulations). 
